Information about Insulin Degludec intermediates

Insulin Degludec intermediates play a vital role in our production and life. It is also used as a pharmaceutical intermediate. So what is the relevant information of Insulin Degludec intermediates? Next, let us take a look.

Here is that the content:

l Adjustment plan

l Conversion of premixed insulin therapy to Insulin Degludec intermediates therapy

Adjustment plan

The blood glucose monitoring program requires at least 3 days a week, and blood glucose is measured 3 to 4 times a day. According to fasting blood glucose, adjust the dosage of Insulin Degludec intermediates to 1 to 4 units, and adjust the dosage of insulin during meals to 1 to 2 units according to the blood glucose level before the three meals. Adjust once every 3-5 days until the blood sugar reaches the target. When conditions permit, hospitalization can also be used in the early stage of insulin therapy, close monitoring of blood glucose, daily adjustment of insulin dosage, which is conducive to stable blood glucose control as soon as possible. In addition, Insulin Degludec intermediates combined with meal insulin therapy can also be combined with oral hypoglycemic drugs. Such as biguanides (BG), a-glycosidase inhibitors (AGI), thiazolidinediones (TZD), dipeptidyl peptidase 4 inhibitors (DPP 4i), glucose transporter 2 inhibitors (S GLT 2i) drugs can be used in combination with basal prandial insulin; glucagon-like peptide 1 receptor agonist (GLP 1 RA) can also be used in combination with basal-prandial insulin, but attention should be paid to the dose of insulin Adjust to prevent the risk of hypoglycemia; the combined use of Insulin Degludec intermediates and insulin secretagogues may increase the risk of hypoglycemia.

Conversion of premixed insulin therapy to Insulin Degludec intermediates therapy

When using premixed insulin to treat poor efficacy, frequent episodes of hypoglycemia, and poor compliance with two pre-mixed insulin injections per day, you can switch from pre-mixed insulin to basic insulin oral hypoglycemic drugs. According to the conversion to Insulin Degludec intermediates for treatment, the initial dosage of Insulin Degludec intermediates can be 60% -80% of the total dose of the original premixed insulin. At the same time, the type and dosage of the patient's oral hypoglycemic drugs need to be adjusted appropriately.

Chengdu Pukang has a professional R&D team with first-class technology, rich experience, and innovative ideas, which can meet the various needs of customers from custom synthesis to mass production. Parking has sufficient resources to provide process development, optimization, and scale-up production. The R & D will cooperate with the production to solve the problems encountered in the pilot scale-up process. We are more professional, more efficient to provide customers with high-quality products. The above is related to the relevant information of Insulin Degludec intermediates. If you are interested in a biology stable solution Insulin Degludec intermediates, injection grade 99% Insulin Degludec intermediates for energy metabolism, lab long-acting solid Insulin Degludec intermediates, TCA cycle synthesis crystal Insulin Degludec intermediates, you can consult our website, our website is www.pu-kang.com. I look forward to your coming and hope to cooperate with you.